ArticleiScience2023

Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.

Katarzyna M Tyc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.